{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:23:40Z","timestamp":1792250620956,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Interv and Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12928-025-01235-1","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:26:29Z","timestamp":1766579189000},"page":"362-371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Limus- versus paclitaxel-coated balloons for coronary in-stent restenosis: meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"41","author":[{"given":"Mohammadreza","family":"Babaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Fallahtafti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Rashedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayyeh","family":"Barati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Khalilipur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ata","family":"Firouzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi H.","family":"Shishehbor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9602-0513","authenticated-orcid":false,"given":"Parham","family":"Sadeghipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"issue":"5","key":"1235_CR1","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.4244\/EIJV17I5A60","volume":"17","author":"F Alfonso","year":"2021","unstructured":"Alfonso F, Kastrati A. Clinical burden and implications of coronary interventions for in-stent restenosis. EuroIntervention. 2021;17(5):e355\u20137.","journal-title":"EuroIntervention"},{"issue":"13","key":"1235_CR2","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.jacc.2020.08.002","volume":"76","author":"ID Moussa","year":"2020","unstructured":"Moussa ID, Mohananey D, Saucedo J, Stone GW, Yeh RW, Kennedy KF, et al. Trends and outcomes of restenosis after coronary stent implantation in the United States. J Am Coll Cardiol. 2020;76(13):1521\u201331.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1235_CR3","doi-asserted-by":"publisher","first-page":"e380","DOI":"10.4244\/EIJ-D-19-01031","volume":"17","author":"H Tamez","year":"2021","unstructured":"Tamez H, Secemsky EA, Valsdottir LR, Moussa ID, Song Y, Simonton CA, et al. Long-term outcomes of percutaneous coronary intervention for in-stent restenosis among Medicare beneficiaries. EuroIntervention. 2021;17(5):e380\u20137.","journal-title":"EuroIntervention"},{"issue":"36","key":"1235_CR4","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the European society of cardiology (ESC) endorsed by the European association for Cardio-Thoracic surgery (EACTS). Eur Heart J. 2024;45(36):3415\u2013537.","journal-title":"Eur Heart J"},{"issue":"9994","key":"1235_CR5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0140-6736(15)60657-2","volume":"386","author":"GC Siontis","year":"2015","unstructured":"Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, P\u00e9rez-Vizcayno MJ, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet. 2015;386(9994):655\u201364.","journal-title":"Lancet"},{"issue":"7","key":"1235_CR6","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jacc.2025.05.062","volume":"86","author":"J Kirtane Ajay","year":"2025","unstructured":"Kirtane Ajay J, Shlofmitz R, Moses J, Bachinsky W, Dohad S, Rudick S, et al. Paclitaxel-coated balloon for the treatment of multilayer in-stent restenosis. J Am Coll Cardiol. 2025;86(7):502\u201311.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1235_CR7","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/jama.2024.1361","volume":"331","author":"RW Yeh","year":"2024","unstructured":"Yeh RW, Shlofmitz R, Moses J, Bachinsky W, Dohad S, Rudick S, et al. Paclitaxel-coated balloon vs uncoated balloon for coronary in-stent restenosis: the AGENT IDE randomized clinical trial. JAMA. 2024;331(12):1015\u201324.","journal-title":"JAMA"},{"issue":"25","key":"1235_CR8","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.123.064473","volume":"147","author":"D Capodanno","year":"2023","unstructured":"Capodanno D, Mehran R, Krucoff MW, Baber U, Bhatt DL, Capranzano P, et al. Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the academic research consortium. Circulation. 2023;147(25):1933\u201344.","journal-title":"Circulation"},{"issue":"14","key":"1235_CR9","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.4161\/cc.5.14.3113","volume":"5","author":"MV Blagosklonny","year":"2006","unstructured":"Blagosklonny MV, Demidenko ZN, Giovino M, Szynal C, Donskoy E, Herrmann RA, et al. Cytostatic activity of Paclitaxel in coronary artery smooth muscle cells is mediated through transient mitotic arrest followed by permanent post-mitotic arrest: comparison with cancer cells. Cell Cycle. 2006;5(14):1574\u20139.","journal-title":"Cell Cycle"},{"issue":"8","key":"1235_CR10","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0735-1097(03)01056-8","volume":"42","author":"B Scheller","year":"2003","unstructured":"Scheller B, Speck U, Schmitt A, B\u00f6hm M, Nickenig G. Addition of Paclitaxel to contrast media prevents restenosis after coronary stent implantation. JACC. 2003;42(8):1415\u201320.","journal-title":"JACC"},{"issue":"8","key":"1235_CR11","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1161\/01.CIR.104.8.852","volume":"104","author":"SO Marx","year":"2001","unstructured":"Marx SO, Marks AR. Bench to bedside. Circulation. 2001;104(8):852\u20135.","journal-title":"Circulation"},{"issue":"24","key":"1235_CR12","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1161\/CIRCULATIONAHA.110.936922","volume":"121","author":"WA Gray","year":"2010","unstructured":"Gray WA, Granada JF. Drug-coated balloons for the prevention of vascular restenosis. Circulation. 2010;121(24):2672\u201380.","journal-title":"Circulation"},{"issue":"9","key":"1235_CR13","first-page":"914","volume":"6","author":"GD Dangas","year":"2013","unstructured":"Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (clinical evaluation of the Xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). JACC: Cardiovascular Interventions. 2013;6(9):914\u201322.","journal-title":"JACC: Cardiovascular Interventions"},{"issue":"18","key":"1235_CR14","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa0910496","volume":"362","author":"GreggW Stone","year":"2010","unstructured":"Stone Gregg W, Rizvi A, Newman W, Mastali K, Wang John C, Caputo R, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362(18):1663\u201374.","journal-title":"N Engl J Med"},{"issue":"14","key":"1235_CR15","first-page":"1794","volume":"16","author":"B Cortese","year":"2023","unstructured":"Cortese B, Testa L, Heang Tay M, Ielasi A, Bossi I, Latini Roberto A, et al. Sirolimus-coated balloon in an all-comer population of coronary artery disease patients. JACC: Cardiovasc Interventions. 2023;16(14):1794\u2013803.","journal-title":"JACC: Cardiovasc Interventions"},{"issue":"13","key":"1235_CR16","doi-asserted-by":"publisher","first-page":"e806","DOI":"10.4244\/EIJ-D-24-00295","volume":"20","author":"Y Chen","year":"2024","unstructured":"Chen Y, Gao L, Qin Q, Zhang J, Jia S, Wu M, et al. Biolimus-coated versus paclitaxel-coated balloons for coronary in-stent restenosis (BIO ASCEND ISR): a randomised, non-inferiority trial. EuroIntervention. 2024;20(13):e806\u201317.","journal-title":"EuroIntervention"},{"issue":"8","key":"1235_CR17","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.jcin.2024.12.024","volume":"18","author":"H Liu","year":"2025","unstructured":"Liu H, Li Y, Fu G, An J, Chen S, Zhong Z, et al. Sirolimus- vs Paclitaxel-Coated balloon for the treatment of coronary In-Stent restenosis: the SIBLINT-ISR randomized trial. JACC Cardiovasc Interv. 2025;18(8):963\u201371.","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"1235_CR18","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jcin.2024.11.026","volume":"18","author":"RA Byrne","year":"2025","unstructured":"Byrne RA, Hahn JY, O\u2019Kane P, Sabat\u00e9 M, Toelg R, Copt S, et al. Randomized trial of Biolimus DCB for in-stent restenosis: the primary results of the REFORM study. JACC Cardiovasc Interv. 2025;18(5):654\u201362.","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"1235_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.124.014677","volume":"18","author":"L Pleva","year":"2025","unstructured":"Pleva L, Kukla P, Kovarnik T, Zapletalova J. Comparing the efficacy of sirolimus and Paclitaxel-Eluting balloon catheters in the treatment of coronary in-stent restenosis: a prospective randomized study (TIS 2 study). Circ Cardiovasc Interv. 2025;18(5):e014677.","journal-title":"Circ Cardiovasc Interv"},{"key":"1235_CR20","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372.","DOI":"10.1136\/bmj.n71"},{"issue":"9","key":"1235_CR21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.122.012305","volume":"15","author":"B Scheller","year":"2022","unstructured":"Scheller B, Mangner N, Abdul Kader M, Wan Ahmad WA, Jeger R, W\u00f6hrle J, et al. Combined analysis of two parallel randomized trials of sirolimus-coated and Paclitaxel-coated balloons in coronary in-stent restenosis lesions. Circ Cardiovasc Interv. 2022;15(9):e012305.","journal-title":"Circ Cardiovasc Interv"},{"issue":"5","key":"1235_CR22","doi-asserted-by":"publisher","first-page":"e014677","DOI":"10.1161\/CIRCINTERVENTIONS.124.014677","volume":"18","author":"L Pleva","year":"2025","unstructured":"Pleva L, Kukla P, Kovarnik T, Zapletalova J. Comparing the efficacy of sirolimus and Paclitaxel-Eluting balloon catheters in the treatment of coronary in-stent restenosis: a prospective randomized study (TIS 2 study). Circ Cardiovasc Interv. 2025;18(5):e014677.","journal-title":"Circ Cardiovasc Interv"},{"issue":"8","key":"1235_CR23","first-page":"963","volume":"18","author":"H Liu","year":"2025","unstructured":"Liu H, Li Y, Fu G, An J, Chen S, Zhong Z, et al. Sirolimus- vs Paclitaxel-Coated balloon for the treatment of coronary in-stent restenosis: the SIBLINT-ISR randomized trial. JACC: Cardiovascular Interventions. 2025;18(8):963\u201371.","journal-title":"JACC: Cardiovascular Interventions"},{"key":"1235_CR24","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"7650","key":"1235_CR25","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"issue":"6","key":"1235_CR26","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jcin.2018.11.040","volume":"12","author":"RM Ali","year":"2019","unstructured":"Ali RM, Abdul Kader M, Wan Ahmad WA, Ong TK, Liew HB, Omar AF, et al. Treatment of coronary drug-eluting stent restenosis by a sirolimus- or Paclitaxel-coated balloon. JACC Cardiovasc Interv. 2019;12(6):558\u201366.","journal-title":"JACC Cardiovasc Interv"},{"issue":"25","key":"1235_CR27","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1161\/CIRCULATIONAHA.104.513952","volume":"111","author":"L Mauri","year":"2005","unstructured":"Mauri L, Orav EJ, Kuntz RE. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation. 2005;111(25):3435\u201342.","journal-title":"Circulation"},{"issue":"3","key":"1235_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jconrel.2012.07.004","volume":"162","author":"WC Carlyle","year":"2012","unstructured":"Carlyle WC, McClain JB, Tzafriri AR, Bailey L, Zani BG, Markham PM, et al. Enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug. J Control Release. 2012;162(3):561\u20137.","journal-title":"J Control Release"},{"key":"1235_CR29","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-E-25-00021","author":"S Fezzi","year":"2025","unstructured":"Fezzi S, Scheller B, Cortese B, Alfonso F, Jeger R, Colombo A, et al. Definitions and standardized endpoints for the use of drug-coated balloon in coronary artery disease: consensus document of the Drug Coated Balloon Academic Research Consortium. EuroIntervention. 2025. https:\/\/doi.org\/10.4244\/EIJ-E-25-00021.","journal-title":"EuroIntervention"},{"issue":"9865","key":"1235_CR30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(12)61964-3","volume":"381","author":"RA Byrne","year":"2013","unstructured":"Byrne RA, Neumann F-J, Mehilli J, Pinieck S, Wolff B, Tiroch K, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2013;381(9865):461\u20137.","journal-title":"Lancet"},{"issue":"15","key":"1235_CR31","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/eurheartj\/ehad026","volume":"44","author":"D Giacoppo","year":"2023","unstructured":"Giacoppo D, Alvarez-Covarrubias HA, Koch T, Cassese S, Xhepa E, Kessler T, et al. Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial. Eur Heart J. 2023;44(15):1343\u201357.","journal-title":"Eur Heart J"},{"key":"1235_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15020060","author":"PM Kulyassa","year":"2025","unstructured":"Kulyassa PM, N\u00e9meth BT, Hizoh I, Jank\u00f3 LK, Ruzsa Z, Jambrik Z, et al. The design and feasibility of optimal treatment for coronary drug-eluting stent in-stent restenosis (OPEN-ISR)-a prospective, randomised, multicentre clinical trial. J Pers Med. 2025. https:\/\/doi.org\/10.3390\/jpm15020060.","journal-title":"J Pers Med"}],"container-title":["Cardiovascular Intervention and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-025-01235-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12928-025-01235-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-025-01235-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:14:11Z","timestamp":1773940451000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12928-025-01235-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1235"],"URL":"https:\/\/doi.org\/10.1007\/s12928-025-01235-1","relation":{},"ISSN":["1868-4300","1868-4297"],"issn-type":[{"value":"1868-4300","type":"print"},{"value":"1868-4297","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Mehdi Shishebor serves as a consultant and advisor to Medtronic, Boston Scientific Corporation (BSC), Abbott, INQUIS Medical, and Antengene Corporation (ANT). All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}}]}}